Skip to main content

View full-text article in PMC

. 2021 Feb 18;15:134–143. doi: 10.1016/j.ijpddr.2021.02.004

Table 2.

Larval development assay results.

	Thiabendazole			Levamisole					Ivermectin aglycone
Time post-replacement	EC⁵⁰ (μM)	Resistance ratio^a	R²	EC⁵⁰ (μM)	Resistance ratio^a	EC⁹⁵ (μM)	Resistance ratio^b	R²	EC⁵⁰ (nM)	Resistance ratio^a	EC⁹⁵ (μM)	Resistance ratio^b	R²
UGA-SUSC	0.03	–	0.92	0.93	–	3.87	–	0.96	0.90	–	2.77	–	0.89
Pre-replacement	12.28	491.00	0.86	0.71	0.76	5.40	1.40	0.90	49.10	54.60	645.43	233.01	0.94
1.5 months	0.03	1.18	1.00	0.94	1.01	2.14	0.55	0.97	2.66	2.96	6.09	2.20	0.98
1.5 years	54.91	2195.52	0.78	1.89	2.02	6.57	1.70	0.96	18.44	20.50	88.45	31.93	0.99
2.5 years	28.61	1143.94	0.78	2.73	2.92	38.53	9.96	0.93	26.12	29.04	108.03	39.00	0.97
3.5 years	17.85	713.71	0.85	2.87	3.07	14.69	3.80	0.82	15.99	17.78	488.51	176.36	0.93

^a

Resistance ratio was calculated as EC50 of tested isolate divided by EC50 of UGA-SUSC.

^b

Resistance ratio was calculated as EC95 of tested isolate divided by EC95 of UGA-SUSC.